Karaca Mustafa, Tural Deniz, Kocoglu Hakan, Selcukbiricik Fatih, Bilgetekin Irem, Özet Ahmet
Department of Medical Oncology, Internal Medicine, Gazi University Medical School, Ankara, Turkey.
Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey.
J Cancer Res Ther. 2018 Apr-Jun;14(3):593-596. doi: 10.4103/0973-1482.172588.
The age-adjusted mortality rate due to gastric cancer was reported to increase with age. This study aims to investigate the results of adjuvant chemotherapy in patients aged 65 years or older comparing with younger patients and focusing on its impact on survival.
A total of 406 patients with nonmetastatic gastric cancer that consisted of 283 patients younger than 65 years (range: 23-64 years) and 123 patients 65 years of age or older (range: 65-75 years) were retrospectively evaluated. Categorical and continuous variables were summarized using the descriptive statistics and compared with Chi-square and Mann-Whitney U-tests, respectively. Cancer-specific survival rates were estimated by the Kaplan-Meier method.
Median age at diagnosis was 58 years (range: 23-75 years). There was no significant difference in gender, tumor localization in the stomach (cardia/noncardia), tumor histology, perineural invasion, lymphovascular invasion, histopathological characteristics of the tumor, and tumor stage between groups. No significant difference was detected in survival between groups. The median survivals were 20.8 months (range: 17-24.6) in patients younger than 65 years and 19.5 months (range: 14.8-24.1) in patients 65 years of age or older (P = 0.9).
We showed that adjuvant chemotherapy in elderly patients with gastric cancer has same effectiveness as nonelderly patients. However, further well-designated prospective studies are needed to confirm these findings.
据报道，胃癌的年龄调整死亡率随年龄增长而增加。本研究旨在调查65岁及以上患者辅助化疗的结果，并与年轻患者进行比较，重点关注其对生存的影响。
对406例非转移性胃癌患者进行回顾性评估，其中283例年龄小于65岁（范围：23 - 64岁），123例年龄在65岁及以上（范围：65 - 75岁）。分类变量和连续变量分别采用描述性统计进行总结，并分别通过卡方检验和曼 - 惠特尼U检验进行比较。采用Kaplan - Meier法估计癌症特异性生存率。
诊断时的中位年龄为58岁（范围：23 - 75岁）。两组在性别、胃内肿瘤定位（贲门/非贲门）、肿瘤组织学、神经周围侵犯、淋巴管侵犯、肿瘤的组织病理学特征以及肿瘤分期方面均无显著差异。两组之间的生存率无显著差异。年龄小于65岁的患者中位生存期为20.8个月（范围：17 - 24.6），65岁及以上患者为19.5个月（范围：14.8 - 24.1）（P = 0.9）。
我们表明，老年胃癌患者辅助化疗与非老年患者具有相同的疗效。然而，需要进一步设计良好的前瞻性研究来证实这些发现。
